NCT06715124 - QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | Biotech Hunter

Enrollment

237

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

January 2, 2027

Study Completion Date

January 2, 2029

Conditions

Advanced Solid Tumors

Interventions

DRUG

QTX3544

QTX3544 will be administered at protocol defined dose.

COMBINATION_PRODUCT

Cetuximab

Cetuximab will be administered at protocol defined dose.

Trial Locations (10)

27705

RECRUITING

Duke Cancer Center, Durham

34232

RECRUITING

Florida Cancer Specialists & Research Institute, Sarasota

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

49546

RECRUITING

South Texas Accelerated Research Therapeutics, LLC Midwest, Grand Rapids

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

78229

RECRUITING

South Texas Accelerated Research Therapeutics, LLC San Antonio, San Antonio

80218

RECRUITING

Sarah Cannon Research Institute, Denver

84112

RECRUITING

Huntsman Cancer Institute, University of Utah, Salt Lake City

84119

RECRUITING

South Texas Accelerated Research Therapeutics Mountain Region, LLC, West Valley City

06511

RECRUITING

Yale Cancer Center, New Haven